-
2022-502980-39-00
5
2024-01-25
Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
-
2022-501316-34-00
4
2023-11-27
Patient cured from a primary cancer and at risk of 2nd cancer
-
2022-501943-34-00
5
2023-06-27
Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
-
2022-500085-96-00
5
2023-03-31
Patients with gambling disorder or sexual addiction or food addiction
-
2024-514351-14-00
4
2023-02-20
Pure cell red aplasia by major ABO mismatch after allogeneic hematopoi
-
2024-511884-27-00
3
2022-11-09
CD205+ve recurrent and/or metastatic tumor types including but not lim
-
2022-500643-20-00
4
2022-09-27
Patients with locally advanced, metastatic or unresectable hepatocellu
-
2023-504660-41-00
4
2022-07-11
Cholestatic Pruritus in Patients with Primary Biliary Cholangitis (PBC
-
2024-510706-86-00
9
2022-05-16
Advanced/ metastatic soft tissue sarcomas
-
2023-509496-16-00
4
2022-04-21
Advanced /metastatic sarcomas: undifferentiated pleomorphic sarcoma, o
-
2024-515310-40-01
4
2021-08-04
Patients with a confirmed diagnosis of ovarian small cell carcinoma.
-
2024-511246-39-00
1
2021-07-27
Solid tumours with HER2 aberrations
-
2024-512953-26-00
5
2021-07-06
intermediate-stage hepatocellular carcinoma
-
2024-512982-15-00
5
2021-06-28
BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metas
-
2024-515344-23-00
4
2021-06-17
local advenced pancreatic adenocarcinoma
-
2022-502737-26-00
4
2020-12-15
epidermoid carcinoma
-
2024-510783-23-00
7
2020-10-29
Fallopian Tube Cancer
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2024-514603-34-00
5
2020-03-02
intermediate-risk differentiated thyroid cancer patients
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2023-508128-37-00
5
2017-07-19
All patients who have been treated with Novartis or Penn CAR T-cell th
-
2024-516078-31-00
10
2015-05-05
Recurrent and Primary Refractory Ewing Sarcoma
-
2024-516063-89-00
5
2025-04-10
Metastatic Pancreatic Ductal Adenocarcinoma
-
2024-518553-41-00
5
2024-11-08
colon cancer and rectal with liver metastasis